文献速递肝病

血糖控制可预测非酒精性脂肪性肝病中肝细胞气球样变和肝纤维化的严重程度

Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Hepatology · 2021-06-02

本研究基于Duke NAFLD临床数据库713例活检证实的NAFLD/NASH患者,探讨肝活检前一年平均HbA1c与组织学严重程度的关系。结果显示平均HbA1c每升高1%,纤维化分期增加的优势比为1.15(95%CI 1.01-1.31);与良好血糖控制相比,中等控制与气球样变(OR 1.74)和肝纤维化(OR 4.59)严重程度增加显著相关。结论提示优化血糖控制可能改变NASH相关纤维化进展风险。

要点

  • 平均HbA1c每升高1%,肝纤维化分期增加风险高15%(OR 1.15)。
  • 中等血糖控制者肝纤维化风险是良好控制者的4.59倍。
  • 血糖控制与气球样变和纤维化严重度相关,与小叶炎症无关。

核心结论

  • 血糖控制可预测NAFLD/NASH患者肝细胞气球样变和肝纤维化的严重程度。
  • 优化血糖控制可能是改变NASH相关纤维化进展风险的手段。

研究设计与样本

  • 基于Duke NAFLD临床数据库的回顾性队列研究,纳入713例活检证实的NAFLD/NASH患者。
  • 队列中位年龄50岁,女性59%,白人84%,糖尿病占49%(n=348)。
  • 采用广义线性回归模型校正年龄、性别、种族、糖尿病、BMI和高脂血症。
  • 对298例有至少3次HbA1c测量的患者进行基于组的轨迹分析。

主要发现

  • 较高的平均HbA1c与更高的脂肪变性和气球样肝细胞分级相关,但与小叶炎症无关。
  • 平均HbA1c每增加1%,纤维化分期增加的优势比为1.15(95%CI 1.01-1.31)。
  • 与良好血糖控制相比,中等控制与气球样肝细胞严重程度增加相关(OR 1.74;95%CI 1.01-3.01;P=0.048)。
  • 与良好血糖控制相比,中等控制与肝纤维化严重程度增加相关(OR 4.59;95%CI 2.33-9.06;P<0.01)。

临床怎么用

  • 在NAFLD/NASH患者管理中,应关注肝活检前一年的平均HbA1c水平。
  • 优化血糖控制可能作为降低NASH相关纤维化进展风险的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histological severity of NASH. APPROACH AND RESULTS: Using the Duke NAFLD Clinical Database, we examined patients with biopsy-proven NAFLD/NASH (n = 713) and the association of liver injury with glycemic control as measured by hemoglobin A1c (HbA1c). The study cohort was predominantly female (59%) and White (84%) with median (interquartile range) age of 50 (42, 58) years; 49% had diabetes (n = 348). Generalized linear regression models adjusted for age, sex, race, diabetes, body mass index, and hyperlipidemia were used to assess the association between mean HbA1c over the year preceding liver biopsy and severity of histological features of NAFLD/NASH. Histological features were graded and staged according to the NASH Clinical Research Network system. Group-based trajectory analysis was used to examine patients with at least three HbA1c (n = 298) measures over 5 years preceding clinically indicated liver biopsy. Higher mean HbA1c was associated with higher grade of steatosis and ballooned hepatocytes, but not lobular inflammation. Every 1% increase in mean HbA1c was associated with 15% higher odds of increased fibrosis stage (OR, 1.15; 95% CI, 1.01, 1.31). As compared with good glycemic control, moderate control was significantly associated with increased severity of ballooned hepatocytes (OR, 1.74; 95% CI, 1.01, 3.01; P = 0.048) and hepatic fibrosis (HF; OR, 4.59; 95% CI, 2.33, 9.06; P < 0.01). CONCLUSIONS: Glycemic control predicts severity of ballooned hepatocytes and HF in NAFLD/NASH, and thus optimizing glycemic control may be a means of modifying risk of NASH-related fibrosis progression.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021. PMID: 33724511. doi:10.1002/hep.31806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。